一分钟看懂
这是一项关于结直肠癌的II 期研究,登记的药物或干预包括Fruquintinib Combined With trifluridine/tipiracil;Bevacizumab combined with trifluridine/tipiracil,当前状态为尚未开始招募。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。
药物或干预
Fruquintinib Combined With trifluridine/tipiracil;Bevacizumab combined with trifluridine/tipiracil · II 期
登记条件中文摘要
年龄范围:18岁至75岁
登记的基本范围为不限性别,年龄18岁至75岁;以下仅摘录8项专业入选条件,需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件,具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息,不代表此刻仍有名额;请向研究中心确认最新情况。
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
入选条件原文摘录
以下为摘录,请打开原始登记查看完整入排标准。
- * Have a full understanding of this study and voluntarily sign the informed consent form;
- * Aged 18-75 years old (including 18 and 75 years old);
- * Diagnosed with advanced metastatic colorectal adenocarcinoma by histopathological examination;
- * Patients who have previously received first-line oxaliplatin and irinotecan treatment, or have received and failed at least two lines of standard chemotherapy regimens. These standard treatment regimens must include fluoropyrimidine-based drugs, oxaliplatin and irinotecan (with or without bevacizumab or cetuximab). Treatment failure is defined as disease progression occurring during treatment or within 3 months after the last treatment, or intolerable toxic side effects. Each line of treatment must include one or more chemotherapy drugs administered for ≥1 cycle; if recurrence or metastasis occurs during adjuvant/neoadjuvant treatment or within 6 months after completion of adjuvant/neoadjuvant treatment, the adjuvant/neoadjuvant treatment is considered a failure of first-line chemotherapy for advanced disease;
- * Have previously received bevacizumab treatment;
- * Must have at least one clear measurable lesion that meets the requirements of the Response Evaluation Criteria in Solid Tumors (RECIST 1.1);
- * ECOG performance status of 0-1;
- * Expected survival time ≥12 weeks;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号:NCT07286695;登记信息更新于 2026-01-21;本站同步于 2026-11-21。